Solid Biosciences (SLDB) Stock Price, News & Analysis

Company Overview

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Key Stats

• Today's Range: $5.66 to $6.07
• 50-Day Range: $4.51 to $7.07
• 52-Week Range: $2.41 to $10.07
• Volume: 794,407 shs
• Average Volume: 1.16 million shs
• Market Capitalization: $461.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Solid Biosciences Stock Analysis - MarketRank™

Solid Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 322nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Solid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Solid Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Solid Biosciences are expected to grow in the coming year, from ($2.84) to ($2.63) per share.

Price to Book Value per Share Ratio

Solid Biosciences has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.88% of the float of Solid Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Solid Biosciences has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Solid Biosciences has recently decreased by 1.17%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solid Biosciences does not currently pay a dividend.

Dividend Growth

Solid Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.88% of the float of Solid Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Solid Biosciences has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Solid Biosciences has recently decreased by 1.17%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.80

News Sentiment

Solid Biosciences has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Solid Biosciences this week, compared to 4 articles on an average week.

Search Interest

Only 33 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 12 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -52% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solid Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.90% of the stock of Solid Biosciences is held by insiders.

Percentage Held by Institutions

81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLDB Stock Analysis - Frequently Asked Questions

How have SLDB shares performed this year?

Solid Biosciences' stock was trading at $4.00 at the beginning of the year. Since then, SLDB stock has increased by 48.3% and is now trading at $5.93.

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) announced its earnings results on Tuesday, August, 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.

When did Solid Biosciences' stock split?

Solid Biosciences shares reverse split on Friday, October 28th 2022.The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Solid Biosciences IPO?

Solid Biosciences (SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' top institutional investors include Redmile Group LLC (2.47%), Nantahala Capital Management LLC (2.20%), MPM Bioimpact LLC (2.10%) and Franklin Resources Inc. (2.06%). Insiders that own company stock include Perceptive Advisors Llc, Alexander Cumbo, Kevin Tan, Carl Ashley Morris, David T Howton, Jessie Hanrahan, Ilan Ganot, Gabriel Brooks, Paul Herzich and Clare Kahn.
View institutional ownership trends.

How do I buy shares of Solid Biosciences?

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/23/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLDB
• CIK: 1707502
• Web: www.solidbio.com
• Phone: (617) 337-4680
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Solid Biosciences: $15.00
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +153.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$124.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.70%
• Return on Assets: -56.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.34
• Quick Ratio: 9.34

Sales & Book Value

• Annual Sales: $8.09 million
• Price / Sales: 57.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.32 per share
• Price / Book: 1.79

Miscellaneous

• Outstanding Shares: 77,870,000
• Free Float: 76,389,000
• Market Cap: $461.77 million
• Optionable: Optionable
• Beta: 2.44